FINAL JUDGMENT AND INJUNCTION PURSUANT TO STIPULATION

Defendant Neurobrands, LLC ("Neuro" or "Defendant"), appearing through its attorneys Liner LLP by Angela Agrusa, Esq. and having accepted service of the complaint;

Plaintiff and Defendant having negotiated and agreed to a settlement including stipulating to the entry of this Final Judgment and Injunction Pursuant to Stipulation ("Judgment") prior to the taking of any proof and without trial or adjudication of any issue of fact or law, and without any admission of liability or wrongdoing regarding any issue, of fact, law or otherwise; and

The Court having considered the pleadings and good cause appearing,

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that Plaintiff have Judgment against Defendant as follows:

JURISDICTION AND VENUE

1. This action is brought under the laws of the State of California. This Court has jurisdiction of the subject matter and the parties. Venue is appropriate in this Court.

APPLICABILITY

 The provisions of this Judgment are applicable to Defendant and its officers, directors, agents, representatives, successors, and assigns acting within the course and scope of their agency or employment and in concert with Defendant.

MONETARY RELIEF

- 3. Pursuant to Business and Professions Code sections 17206 and 17536, Defendant shall pay to Plaintiff the total sum of \$500,000 within 120 days of the entry of Judgment. This sum shall be paid as follows:
 - a. Within 30 days of the entry of Judgment, a check in the amount of \$40,000 payable to the Consumer Protection Prosecution Trust Fund as *cy pres* restitution,

- mailed to Adam Radinsky, Chief Deputy, Consumer Protection Division, Santa Monica City Attorney's Office, 1685 Main St., Room 310, Santa Monica, CA 90401;
- b. Within 30 days of the entry of Judgment, a check for \$80,000 payable to the Los Angeles County District Attorney's Office for civil penalties and investigative costs, mailed to Kathleen Tuttle, Deputy District Attorney, 211 W. Temple Street, 10th Floor, Los Angeles, CA 90012;
- c. Within 30 days of the entry of Judgment, a check for \$80,000 payable to the Santa Monica City Attorney's Office for civil penalties and investigative costs, mailed to Adam Radinsky, Chief Deputy, Consumer Protection Division, Santa Monica City Attorney's Office, 1685 Main St., Room 310, Santa Monica, CA 90401;
- d. Within 90 days of the entry of Judgment, a check in the amount of \$60,000 payable to the Consumer Protection Prosecution Trust Fund as cy pres restitution, mailed to Adam Radinsky, Chief Deputy, Consumer Protection Division, Santa Monica City Attorney's Office, 1685 Main St., Room 310, Santa Monica, CA 90401;
- e. Within 90 days of the entry of Judgment, an additional payment of \$120,000 payable to the Los Angeles County District Attorney's Office for civil penalties and investigative costs mailed to Kathleen Tuttle, Deputy District Attorney, 211 W. Temple Street, 10th Floor, Los Angeles, CA 90012;
- f. Within 90 days of the entry of Judgment, an additional payment of \$120,000 payable to the Santa Monica City Attorney's Office for civil penalties and investigative costs mailed to Adam Radinsky, Chief Deputy, Consumer Protection Division, Santa Monica City Attorney's Office, 1685 Main St., Room 310, Santa Monica, CA 90401;
- g. The parties have stipulated and the Court finds that it is impractical and impossible to identify or to provide direct restitution to consumers who may have

relied on the marketing statements challenged in this case. Thus Defendant shall pay restitution under the doctrine of *cy pres* pursuant to Business and Professions Code sections 17203 and 17535 as described above in this paragraph.

- h. Defendant may make any payments earlier or in greater amounts than the above, as long as the full amount of \$500,000.00 is paid within 90 days of the entry of this Judgment and is consistent with the allocations described above.
- In the event Defendant fails to make any of the above payments within five days
 of its due date, the full remaining amount under the Judgment then due shall
 become due and owing immediately.
- 4. The Parties shall bear their own attorneys' fees and costs, except as provided in paragraph 3.

GENERAL INJUNCTIVE TERMS

- 5. Pursuant to Business and Professions Code sections 17203 and 17535, Neuro is permanently enjoined and restrained from directly or indirectly engaging in any of the following acts or practices:
 - a. Making or causing to be made any false or misleading statement about
 Defendant's products that form the basis of the allegations in the
 Complaint (filed concurrently herewith) in connection with the
 advertising, labeling, or sale of any such product in violation of
 Business and Professions Code section 17500.
 - b. Making or disseminating any representation about the effects, efficacy, or other aspects of Defendant's products that form the basis of the allegations in the Complaint (filed concurrently herewith) unless such representation is true, not misleading, and Defendant has in its possession and relies upon COMPETENT AND RELIABLE SCIENTIFIC EVIDENCE that substantiates such representation. (For

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

c.

purposes of this Judgment, the term "COMPETENT AND RELIABLE SCIENTIFIC EVIDENCE" means tests, analyses, research, studies, or other evidence based upon the expertise of professionals in the relevant area that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the scientific community to yield accurate and reliable results.)

Making or disseminating any of the following claims, using either the same or equivalent language, with respect to Defendant's products, unless they are supported by the results of a new clinical trial designed and executed in accordance with standards and methods generally accepted within the relevant scientific community to produce reliable and accurate results and supported by COMPETENT AND RELIABLE SCIENTIFIC EVIDENCE consistent with the standards and obligations imposed by federal and state law and other applicable rules governing the substantiation of marketing claims:

- i. support(s) memory
- ii. provide(s) fuel for the brain
- iii. promote(s) healthy aging
- iv. provide(s) mental energy
- v. deliver(s) sustained focus
- vi. strengthen(s) your focus and creativity
- vii. enhance(s) mood
- viii. daily dose of immunity
- ix. relieve(s) muscle cramps
- x. help(s) normalize sleep patterns

	_
	3
	4
	5
	6
	7
	8
	9
1	0
1	1
12	2
13	3
14	1
1:	5
16	5
1	7
18	3
19)
20)
21	Į
22)
23	}
24	ļ.
25	į
26	

28

1

2

đ.

Unless it is supported by the results of a new clinical trial designed and executed in accordance with standards and methods generally accepted within the relevant scientific community to produce reliable and accurate results and supported by COMPETENT AND RELIABLE SCIENTIFIC EVIDENCE consistent with the standards and obligations imposed by federal and state law and other applicable rules governing the substantiation of marketing claims, using the term "reduce(s) stress" in the advertising, labeling, or course of sale of any of Defendant's products except as follows:

- i. only in reference to Neuro Bliss;
- ii. only if followed immediately by an asterisk of the same font and typeface-size as the words "reduce(s) stress"; and
- iii. only if accompanied by the following disclaimer which shall be printed on the same side of the label as the asterisk (if on a product) or in close proximity to the asterisk if in any other format (including online, screen or print) and shall be at least as large as the surrounding text: "*May reduce stress temporarily."

e. Using the term "dietary supplement" in the advertising, labeling, or sale of any of Defendant's products except Neuro Sleep.

MARKETING OF PRODUCTS AS FOODS OR DIETARY SUPPLEMENTS

6. Plaintiff and Defendant agree and acknowledge, and the Court orders, that Defendant's products Neuro Bliss, Neuro Sonic and Neuro Daily will henceforth be labeled and marketed as conventional foods as defined under federal law including 21 U.S.C. §312(ff)(2)(B) and the other rules promulgated by the U.S. Food and Drug Administration ("FDA") (collectively, "THE FDA RULES"). Defendant shall market those products in compliance with THE FDA RULES. Defendant shall not market those products as dietary supplements.

- 7. Starting within 90 days after entry of Judgment, Defendant shall market Neuro Sleep only as a dietary supplement under THE FDA RULES.
- 8. Defendant shall give written notice to all of its RESELLERS (which means all wholesale or retail businesses that distribute or sell Defendant's products) of the requirement in this Judgment that Neuro Sleep must be marketed only as a dietary supplement under the FDA rules. This notice shall be included in the term summary described below in Paragraphs 12 and 13.

CAFFEINE LEVEL IN NEURO SONIC

9. Within 90 days after entry of this Judgment, Defendant, in its sole discretion, shall either: (1) limit the amount of caffeine in a serving of Neuro Sonic to a maximum of 0.02 percent in accordance with 21 C.F.R. § 182.1180; or (2) include a level of caffeine in Neuro Sonic only if that level is "Generally Recognized As Safe" (or "GRAS") in accordance with FDA's GRAS Notification Program. Defendant shall promptly inform the People's counsel in writing of submissions and correspondence between Defendant and FDA on the issue of the GRAS status of Neuro Sonic's caffeine content, including providing copies of such correspondence and the caffeine percentage of NeuroSonic if Defendant elects to rely on option (2).

NEW STUDIES OF PRODUCTS

10. Within three years after or prior to entry of this Judgment, Defendant shall conduct or shall have conducted at least one human study each of Neuro Sonic, Neuro Bliss, Neuro Daily, and Neuro Sleep. Defendant may use the clinical findings of those studies in developing marketing claims in accordance with the relevant legal standards specified in this Judgment. Defendant will control the design and implementation of these studies and shall provide the published results of all such studies to the People's counsel. Defendant may elect in its sole discretion to discontinue the sale of a product rather than to design and implement such a human study.

COMPLIANCE

- 11. For the purpose of securing compliance with the terms of this Judgment, Defendant shall within 30 days after entry of Judgment serve each of its officers, directors, and executive managers with a copy of this Judgment.
- 12. Within 30 days after entry of this Judgment, Defendant shall serve on all of its RESELLERS in the state of California by Certified Mail a document that summarizes certain terms of this Judgment in the form attached hereto and incorporated as Exhibit A.
- 13. Within 30 days after entry of this Judgment, Defendant shall serve by Certified Mail on the corporate offices of the 21 companies listed in Exhibit B (1) a Notice regarding Neuro Sleep, in the form attached hereto and incorporated as Exhibit B, along with (2) a written request that said corporate offices forward copies of the Notice to all of their companies' Neuro RESELLERS in the U.S. and provide Neuro with documentation that said notices were given.
- 14. Defendant shall keep custody of all documentation of its compliance with the notice and recordkeeping requirements of this Judgment. Defendant shall provide such items to the People's counsel upon reasonable notice.
- 15. After the date of entry of this Judgment, Defendant shall not manufacture, produce, ship, or deliver any products not in compliance with this Judgment. The deadline in this paragraph shall be extended to June 30, 2016 for the products Neuro Bliss and Neuro Sleep only.
- 16. After the date of entry of this Judgment, Defendant shall not label, advertise or market any products not in compliance with this Judgment. However, claims appearing on the labels of Defendant's products that already were produced, packaged and labelled prior to the entry of this Judgment are exempt from the requirements of this paragraph for a period of nine months following the entry of Judgment. The deadline applicable to claims on labels in the preceding sentence shall be extended to March 30, 2017 for the products Neuro Bliss and Neuro Sleep only.
- 17. Products not in compliance with this Judgment shall not be sold after the respective deadlines contained in the preceding Paragraph. Nothing in this Paragraph creates any additional

liability or duties on the part of Defendant as long as it complies with the remaining paragraphs of this Judgment.

18. Defendant shall promptly provide the production dates of products in the marketplace in response to reasonable requests from the People, to the extent possible or practicable.

MEET AND CONFER

19. Prior to pursuing in court any action against Defendant for violating an affirmative obligation created by this Judgment other than the payment of money, the People agree first to notify Defendant in writing of the alleged violation, engage in good faith efforts informally to resolve the issue, and to allow Defendant fifteen calendar days to correct the alleged violation before seeking such relief.

OTHER PROVISIONS

- 20. Nothing in the Complaint in this action, the accompanying Stipulation, this Judgment, the negotiations leading up to these filings, or any action taken to carry them out shall be construed as an admission of fault or liability by Defendant or by any entity, individual, or organization involved in the settlement of this action.
 - 21. The Parties waive the right to appeal this Judgment as to form or content.
- 22. This Judgment shall constitute a release of Defendant and its officers, directors, employees, agents, representatives, parents, subsidiaries, related entities, successors and assigns from all claims by the People pertaining to or arising from any of the alleged unlawful acts and practices described in the Complaint which occurred prior to the entry of this Judgment.
 - 23. Notices under this Judgment shall be served as follows:

To the People or People's counsel: Adam Radinsky City Attorney's Office 1685 Main Street, Room 310 Santa Monica, CA 90401

To Defendant or Defendant's counsel: Angela Agrusa Liner LLP 1100 Glendon Avenue, 14th floor Los Angeles, CA 90024

- 24. Nothing in this Judgment shall be construed as relieving Defendant of its obligations to comply, or as prohibiting Defendant from complying, with all applicable local, state and federal laws, regulations or rules, nor shall any of the provisions of this Judgment be deemed permission to engage in any acts or practices prohibited by such laws, regulations or rules.
- 25. Pursuant to Business and Professions Code section 17203 and the Court's inherent authority, the Court shall retain jurisdiction for the purpose of enforcing this Judgment and enabling any party to this Judgment to apply to the Court for such further orders and directions as necessary and appropriate to construe, carry out, enforce, interpret, or modify this Judgment, or to redress violations of this Judgment.
- 26. Defendant shall be bound by this Judgment immediately upon its filing and without the filing of a Notice of Entry of Final Judgment.
 - 27. The parties agree that the clerk may enter this Judgment immediately.

Dated: 0pw · 12, 20/6

JUDGE OF THE SUPERIOR COURT LISA HART COLE

EXHIBIT "A"

2

1

3

4

5

7 8

9

10

11 12

13

14 15

16 17

18

19

20 21

22

23

24

25 26

27

28

NOTICE

TO SELLERS AND DISTRIBUTORS OF NEUROBRANDS PRODUCTS

This notice is provided by NeuroBrands LLC and pertains to the distribution and sale of the following Neuro drinks: Neuro Sonic, Neuro Bliss, Neuro Daily, and Neuro Sleep. A court-ordered judgment requires NeuroBrands to comply with the following:

NEUROSLEEP: Effective July 1, 2016:

- Neuro Sleep is the ONLY NeuroBrands drink that will be marketed as a liquid dietary supplement, marketing with the Supplement Facts and "Nutritional Supplement" standard of identity appearing on the bottom portion of the principle display panel.
- As a liquid dietary supplement drink differing from the other Drink Neuro offerings, this product should be merchandised and displayed in a section of the store where other dietary supplement products are displayed - and not in the same location as regular beverages, whenever possible. Merchandising of Neuro Sleep will clearly display the banner "Dietary Supplement" to communicate to consumers the drink is not a conventional beverage.
- Consumers inquiring about Neuro Sleep should be informed the drink is a liquid dietary supplement and not a conventional beverage.
- If consumers have inquiries on the safety qualifications of Neuro Sleep, store representatives or appropriate personnel should point the consumer to the back panel of the bottle which displays the asterisk: "For more information on healthy sleep and the safe use of melatonin, visit www.drinkneuro.com/neurosleep." NeuroBrands personnel will help with this transition.

NEUROSONIC: Effective as of January 1, 2017:

- Any Neuro Sonic bottles MUST display a Nutrition Facts panel and be represented as a conventional food. Product displaying "Supplement Facts" and displaying "Nutritional Supplement" on the principle display panel must not be merchandised or sold;
- The following claims are no longer permitted with the merchandising and/or sale of Neuro Sonic until such time as NeuroBrands has been authorized:
 - Supports memory
 - o Provides fuel for the brain
 - o Promotes healthy aging
 - o Provides mental energy
 - o Delivers sustained focus
 - Strengthens your focus and creativity

FINAL JUDGMENT AND INJUNCTION PURSUANT TO STIPULATION

EXHIBIT "B"

1 2 Notice to be served on the corporate offices of the following companies: 3 1. Wal-Mart 4 2. Kroger 5 3. Target 6 4. Albertsons Safeway 7 5. Publix 8 6. Quick Trip 9 7. CVS 10 8. Walgreens 11 9. Sheetz 12 10. Marathon Petroleum 13 11. Rite Aid 14 12. Race Trac 15 13. Chevron 16 14. Ahold Giant 17 15. Delhaize 18 16. HEB 19 17. Love's

> 18. Ahold Stop & Shop 19. Winn Dixie BiLo

20. Circle K

21. Amazon.com

25 26

20

21

22

23

24

27

NOTICE TO SELLERS AND DISTRIBUTORS OF NEUROBRANDS PRODUCTS

This notice is provided by NeuroBrands LLC and pertains to the sale of Neuro Sleep. A court-ordered judgment requires that effective July 1, 2016:

- Neuro Sleep is the ONLY NeuroBrands drink that will be marketed as a liquid dietary supplement, marketing with the Supplement Facts and "Nutritional Supplement" standard of identity appearing on the bottom portion of the principle display panel.
- As a liquid dietary supplement drink differing from the other Drink Neuro offerings, this product should be merchandised and displayed in a section of the store where other dietary supplement products are displayed and not in the same location as regular beverages, whenever possible. Merchandising of Neuro Sleep will clearly display the banner "Dietary Supplement" to communicate to consumers the drink is not a conventional beverage.
- Consumers inquiring about Neuro Sleep should be informed the drink is a liquid dietary supplement and not a conventional beverage.
- If consumers have inquiries on the safety qualifications of Neuro Sleep, store representatives or appropriate personnel should point the consumer to the back panel of the bottle which displays the asterisk: "For more information on healthy sleep and the safe use of melatonin, visit www.drinkneuro.com/neurosleep." NeuroBrands personnel will help with this transition.

If you have any questions regarding this Notice, please contact Zach Hotle, zach@drinkneuro.com. Thank you for your cooperation and for your continued business with NeuroBrands LLC.